# About PT-141 Score: An Independent Research Digest | PT-141 Score

> PT-141 Score is an independent editorial project that publishes cited summaries of the peer-reviewed bremelanotide literature. Not a clinic, not a vendor, not a prescription.

An independent editorial project that reads the published PT-141 (bremelanotide) literature the way a score reads music — measured, cited, and honest about where the signal is faint.

## What this project is

PT-141 Score is an independent editorial project that publishes summaries of the peer-reviewed research literature on PT-141 (bremelanotide). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

We took the name "Score" because bremelanotide is, at heart, a drug about signal — it enters the brain's own desire circuitry rather than acting on blood flow, and the pivotal human evidence is literally a brain-imaging readout of that circuit responding. Staging the literature as a score lets us draw each finding at its true amplitude: the modest RECONNECT effect honestly small, the tolerability passage honestly loud, the critics' re-analyses audible as a counter-line. The lyricism is in service of the data, never a substitute for it.

## What "script" means here, and what it does not

The "script" in this domain is the manuscript register — a written program of what the research plays — not a prescription pad and not a pharmacy checkout. We do not write, fill, or facilitate prescriptions, and we are not a storefront. No dose on this site is guidance for any individual; labeled and trial doses appear only as reported findings.

We also keep two registers visibly separate. Cited research is the written stave: precise, sourced, on-pitch. Anecdotal community accounts — the "field reports" — are the off-stave, by-ear aside, quarantined in their own visual key and labeled as unverified so an anecdote can never be mistaken for a measured finding. That separation is the editorial honesty this subject demands.

## How we handle accuracy

Every quantitative clinical claim is tied to a specific source: a peer-reviewed trial, a ClinicalTrials.gov record, or the FDA prescribing information. Where the literature is contested, we surface the contest rather than hide it — the re-analyses that call the effect small, the Expression of Concern on the disputed 2008 study, the abstracts that sit below peer-reviewed full text in evidence weight.

We describe what was studied, in whom, at what dose, by what route, and what was measured. We do not recommend, prescribe, or endorse, and we avoid drug brand names in favor of the generic designations PT-141 and bremelanotide. The full source list lives on the [full reference list](/references).

---

PT-141 Score reads the bremelanotide record like a program — the one approved use and the nausea-led tolerability cost set loud and first, the modest effect drawn honestly small beside the re-analyses that contest it, and the unverified field reports kept off-stave in their own key; no clinic behind the score and nothing here dosed, prescribed, or sold.